XML 29 R20.htm IDEA: XBRL DOCUMENT v3.7.0.1
Income Taxes
12 Months Ended
Dec. 31, 2016
Income Tax Disclosure [Abstract]  
Income Taxes
Note 13—Income Taxes
 
For the years ended December 31, 2016 and 2015, the Company recorded no tax provision or benefit. While the Company has incurred losses from operations it has not recorded an income tax benefit for 2016 or 2015 as it has recorded a valuation allowance against net operating losses and other net deferred tax assets due to uncertainties related to the ability of these tax assets to be realized.
 
Deferred tax assets and liabilities are determined based on the difference between financial statement and tax bases using enacted federal and state tax rates in effect for the year in which the differences are expected to reverse. As of December 31, 2016 and 2015, the expected income tax effect of the Company’s deferred tax assets (liabilities) consisted of the following:
 
 
 
2016
 
2015
 
Deferred tax asset:
 
 
 
 
 
 
 
Tax effect of:
 
 
 
 
 
 
 
Net operating loss carryforwards
 
$
31,398,000
 
$
29,122,000
 
Accrued expenses
 
 
19,000
 
 
87,000
 
Amortization of definite lived intangible assets
 
 
––
 
 
10,000
 
Non-qualified stock option compensation
 
 
598,000
 
 
315,000
 
Depreciation
 
 
68,000
 
 
72,000
 
Deferred revenue
 
 
943,000
 
 
880,000
 
Other
 
 
1,000
 
 
139,000
 
Patents
 
 
––
 
 
(23,000)
 
Deferred gain on installment sale
 
 
(1,000)
 
 
––
 
State net operating loss carryforwards, net of federal tax benefit
 
 
929,000
 
 
579,000
 
Research tax credit carryforwards
 
 
2,433,000
 
 
2,274,000
 
Total deferred tax assets
 
 
36,388,000
 
 
33,455,000
 
Valuation allowance
 
 
(36,388,000)
 
 
(33,455,000)
 
Net deferred tax assets
 
$
-
 
$
-
 
 
As of December 31, 2016, the Company had gross net operating loss (NOL) and research tax credit carryforwards of approximately $94.9 million and $1.7 million, respectively, for federal income tax purposes, expiring in varying amounts through the year 2036. Of the $94.9 million NOL carryforward, $2.5 million relates to stock-based compensation and has not been reflected in the deferred taxes and when the benefit of these losses, if any, is realized, the Company will credit additional paid in capital.
 
As of December 31, 2016, the Company had gross NOL and research tax credit carryforwards of approximately $17.6 million and $1.1 million for state income tax purposes, expiring in varying amounts through the year 2036.
 
The Company’s ability to use its NOL and tax credit carryforwards to reduce future taxes is subject to the restrictions provided by Section 382 of the Internal Revenue Code of 1986. These restrictions provide for limitations on the Company’s utilization of its NOL and tax credit carryforwards following a greater than 50% ownership change during the prescribed testing period. On March 5, 2003, the Company had such a change. As a result, all of the Company’s NOL carryforwards as of that date are limited as to utilization. The annual limitation may result in the expiration of certain of the carryforwards prior to utilization. In addition, the Company’s equity offerings, including those in May 2013, December 2014 and July 2016, may have resulted in qualifying changes in ownership. A formal study, which the Company has not undertaken, is required to determine applicability of restrictions, and might indicate that the Company’s NOL carryforwards are subject to additional limitations on utilization.
 
The Company is subject to taxation in the United States and the Commonwealth of Massachusetts. As of December 31, 2016, tax years for 2013, 2014 and 2015 are subject to examination by the tax authorities. Since the Company is in a loss carry-forward position, the Company is generally subject to U.S. federal and state income tax examinations by tax authorities for all years for which a loss carry-forward is utilized.  However, carryforward attributes from prior years may still be adjusted upon examination by tax authorities if they are used in an open period.
 
The benefit for income taxes differs from the federal statutory rate due to the following:
 
 
2016
 
2015
 
Tax at statutory rate
 
(34.0)
%
 
(34.0)
%
State taxes, net of federal benefit
 
0.0
 
 
0.0
 
Research and development credit
 
(0.69)
 
 
(1.3)
 
Share based payment expense
 
0.0
 
 
1.6
 
Other
 
0.42
 
 
0.7
 
Removal of deferred tax asset on federal net operating losses
 
0.00
 
 
0.0
 
Establishment of deferred tax asset on state net operating losses and state deferred taxes, net of federal income tax benefits
 
(5.3)
 
 
(4.9)
 
Change in valuation allowance
 
39.6
 
 
37.9
 
Effective tax rate
 
0.0
%
 
0.0
%